Neuroblastoma: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• MYCN 0
• AKT 0
• TP53 0
• ALK 3
• B7-H3 7
• ERK 0
• PI3K 0
• MAPK 1
• SNCA 0
• mTOR 0
• NRF2 0
• NRAS 0
• AMPK 0
• BCL-2 0
• EZH2 0
• JNK 0
• KRAS 0
• MYC 0
• PPAR 0
• STAT3 0
• STING 1
• CDK4/6 0
• NTRK 0
• RAS 1
• SIRT1 0
• CD19 3
• PARP 2
• TDP-43 0
• VEGF 1
• BDNF 0
• HDAC 0
• HMGB1 0
• ROS1 1
• YAP 0
• BRAF 0
• FAK 0
• HIF-1 0
• IL-1 0
• IL-15 3
• MEK 0
• NLRP3 0
• PINK1 0
• PTEN 0
• APP 0
• BACE1 0
• CD47 0
• CGRP 0
• EGFR 1
• FGFR 0
• GPX4 0
• IDH 1
• IL-6 0
• MAPT 0
• MDM2 0
• PD-1 0
• PD-L1 0
• RET 0
• SOD1 0
• TFEB 0
• TNF 0

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · K99

  Developing GFRA2 as an optimal immunotherapeutic target for neuroblastoma and Ewing sarcoma

  Children's Hosp of Philadelphia· Philadelphia, United States· US$109,364 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R44

  Preparing for Phase I IND For Paradigm Shifting Alpha Radiotherapy [211At]PTT to Treat Ovarian Cancer

  Trevarx Biomedical, Inc.· Philadelphia, United States· US$1,174,824 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R43

  Remote-Controlled PC-CAR T-Cell Therapy for Hard-to-Treat Solid Tumors

  Mabswitch, Inc.· Van Nuys, United States· US$399,998 awarded in fiscal year 2026· until Aug 2027

• NIH NINDS · UG3

  Augmenting immunotherapy pharmacodynamics in glioma

  Mayo Clinic Rochester· Rochester, United States· US$712,838 awarded in fiscal year 2026· until Aug 2028

• NIH NCI · R01

  Investigating the Molecular Effects of Social Deprivation on Neuroblastoma Tumorigenesis and Progression

  University of Michigan at Ann Arbor· Ann Arbor, United States· US$558,294 awarded in fiscal year 2026· until Aug 2031

• European Commission (Horizon Europe) · HORIZON-RIA

  Phase I/II trial of an Oral ER-stress iNducer in relapsed/refractory neuroblastoma and paediatric solid tumours (PHOENIX)

  Fundacio Hospital Universitari Vall D'hebron - Institut de Recerca· Barcelona, Spain· EU contribution €8,468,780· until May 2032· 6 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  CamoUflaged nanopaRticle-driven duAl Therapy to eradicate aggressIVe nEuroblastoma (CURATIVE)

  Universidad de Navarra· Pamplona, Spain· EU contribution €194,075· until May 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Engineered Nanomaterials as Adjuvants to Boost Neuroblastoma Vaccine Efficacy (NANO-ADJUVANT)

  Royal College of Surgeons in Ireland· Dublin 2, Ireland· EU contribution €268,569· until Apr 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  ALK-driven cancers: a Portfolio of ONcoimmunoTherapies to achieve tumor Eradication (A-PONTE)

  Universita Degli Studi di Torino· Torino, Italy· EU contribution €2,497,392· until Dec 2030

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  EURopean Epitranscriptomics of Cancer Academy (EURECA)

  Erasmus Universitair Medisch Centrum Rotterdam· Rotterdam, Netherlands· EU contribution €4,157,935· until Oct 2029· 8 countries

10 of 209 running projects, newest first. Listed amounts together: US$165.2m + €57.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 15
• Organoids 2
• Mendelian Randomization Analysis 5
• CRISPR-Cas Systems 5
• Gene Expression Profiling 45
• Sequence Analysis, RNA 5
• Whole Genome Sequencing 4
• Proteomics 20
• Metabolomics 12
• Mass Spectrometry 10
• Flow Cytometry 19
• Immunohistochemistry 20
• Liquid Biopsy 3
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 65
• Positron-Emission Tomography 14
• Magnetic Resonance Imaging 21
• Machine Learning 12
• Deep Learning 4
• Cohort Studies 8
• Genome-Wide Association Study 5

• Regulatory mechanisms driven by functional 3'-UTR variants in alcohol use disorder and related traits.

  Genome Biol, Jun 2026

• The causal relationship between immune cells and neuroblastoma: a Mendelian randomization study.

  Mol Neurobiol, Nov 2025

• Causal Relationship Between Galectins With Neuroblastoma: A Mendelian Randomization Study.

  Mol Neurobiol, Nov 2025

• Causal links between congenital malformations, birth weight, and neuroblastoma: insights from Mendelian randomization.

  BMC Pediatr, Nov 2025

• Circulating vitamin D concentration and risk of seven cancers: Mendelian randomisation study.

  BMJ, Oct 2017

See which targets of this disease your abstract mentions, and go to the people working on them.